Oh my god, sometimes the insanity of medical patenting and patent laws just can't be captured with words. This below is from the blog Maxspeak - something to think about when your are gurgling your last pneumonic breaths a few months from now...
One of the key issues is whether the government should be stockpiling large quantities of Tamiflu, the drug deemed most effective in combating Avian Flu. The major obstacle to large-scale stockpiling is that the drug is under patent by Roche, the Swiss pharmaceutical company. Roche has limited manufacturing capacity for Tamiflu, and would charge a high price in any case. Roche has been pressured to license the manufacture of Tamiflu to other companies, but has thus far resisted this pressure. Roche, with the support of the pharmaceutical industry, has claimed that forcing it to license Tamiflu would reduce incentives to develop new drugs. It has also claimed that the manufacturing process is so complex that it would take 2 years for other companies to get facilities up and running in any case.
It turns out that the claim on manufacturing complexity is not accurate. The Indian drug manufacturer, Cipla, determined how to reverse engineer the drug in two weeks and is now prepared to begin making a generic version of the drug available in January. (For those not familiar with Cipla, it is one of the world’s largest producers of generic drugs and its products routinely meet the highest safety standards.) So, we are left with the prospect that millions of people in the United States could risk death because our government does not want to infringe on Roche’s patent monopoly.
No comments:
Post a Comment